FDA Approved: STEGLATRO — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

The FDA approved a supplemental application for STEGLATRO (ertugliflozin) filed by Merck Sharp & Dohme LLC, resulting in changes to the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• STEGLATRO (ertugliflozin)

Snippet

SUPPL AP for STEGLATRO (ERTUGLIFLOZIN)